A GLOBAL LEADER IN EPIGENETICS

INVESTOR PRESENTATION

MADX: ORY

OCTOBER 2019

LEGAL NOTICE

DISCLAMER

This document has been prepared by Oryzon Genomics, S.A. exclusively for use during the presentation. Oryzon Genomics, S.A. does not assume liability for this document if it is used with a purpose other than the above. The information and any opinions or statements made in this document have not been verified by independent third parties; therefore, no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Oryzon Genomics, S.A. does not assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement. Information in this document about the price at which securities issued by Oryzon Genomics, S.A. have been bought or sold in the past or about the yield on securities issued by Oryzon Genomics, S.A. cannot be relied upon as a guide to future performance.

IMPORTANT INFORMATION

This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of Law 24/1988, of 28 July, on the Securities Market, Royal Decree-Law 5/2005, of 11 March, and/or Royal Decree 1310/2005, of 4 November, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Oryzon Genomics, S.A. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentationis not an offer of securities for sale in the United States. The Company’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company’s securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

ORYZON

Company Highlights

- A **clinical stage** biopharmaceutical company developing innovative therapies in the field of **Epigenetics**
- **Two molecules** already with **positive data in humans**
- Large IP portfolio with technology fully developed in-house
- MADX: ORY A **publicly traded** company on the **Spanish Stock Exchange**
- Integrated in the **IBEX Small Cap Index**

BOLSA DE MADRID

IBEX Small Cap

- **Raised an aggregate of circa €85M** (in 2015-2019)
- **Cash runway** expected till **2H2021***
- One of the most **LIQUID** companies in the MicroCap group in the Spanish Stock Market
  - 45.7 M Shares outstanding. Fully diluted
  - 350,000 daily volume (Avg Traded Volume in 2018)
  - +88M shares negotiated in 2018 / ≈5 months for share full turnover

ORYZON GENOMICS SA
BALANCE SHEET DATA (UNAUDITED)[1]
(Amounts in thousands US $)

	June 30th, 2019	June 30th, 2018
Cash and cash equivalents	27,868	30,986
Marketable securities	669	165
Total Assets	73,125	68,352
Deferred revenue	0	0
Total Stockholders' equity	50,888	40,697

[1] *Spanish GAAPs*

* On July 26th, the company completed a Private Placement with International Investors raising gross proceeds of €20M (circa $22.2M at the exchange rate on that day)

ORYZON

Epigenetic Modifications : New Targets for Drug Development

- Epigenetic dysfunctions are associated with aberrant gene expression and disease
- Epigenetic drugs can restore these transcriptional imbalances
- Lysine specific histone demethylase 1 (LSD1), aka KDM1A, removes methyl marks at mono- and dimethyl-H3K4 (histone H3 lysine 4) and H3K9 (histone H3 lysine 9)
- LSD1 is the most abundant histone demethylase in the prefrontal cortex



Figure from Arrowsmith et al. *Nature Reviews Drug Discovery* **volume 11** (2012)



Lysine specific histone demethylase 1 (LSD1): an epigenetic "eraser" that removes methyl groups from histones

LSD1 expression and activity can both block and promote gene expression

LSD1 plays a important role in cancer, CNS, inflammatory and viral diseases

ORYZON

Oryzon is pioneering epigenetics in CNS and active in oncology

A broad pipeline to address unmeet medical needs with an attractive market opportunity

INDICATION	STUDY*	RESEARCH	PRECLINICAL	PHASE I	PHASE IIA	PHASE IIB	PHASE III
VAFIDEMSTAT (ORY-2001) - CNS optimized LSD1 inhibitor							
Aggression in BPD	REIMAGINE / PORTICO (*)						
Aggression in ADHD	REIMAGINE / ENTRANCE (*)						
Aggression in ASD	REIMAGINE / COLONNADE (*)						
Aggression in AD	REIMAGINE-AD / GATEWAY (**)						
Alzheimer's disease (Mild Moderate)	ETHERAL monotherapy						
Multiple Sclerosis (RR & SP)	SATEEN monotherapy						
IADADEMSTAT (ORY-1001) - selective LSD1 inhibitor							
AML (Elderly Unfit)	ALICE Combo w Aza						
SCLC (First Line Relapsed)	CLEPSIDRA Combo w Platinum/Etoposide						
ORY-3001 - selective LSD1 inhibitor							
Non Oncological	Preclinical finished						
OTHER PROGRAMS							
Undisclosed							

* IN BLUE, NEW PHASE IIB STUDIES UNDER PREPARATION OR EVALUATION
** Contingent to + results in REIMAGINE-AD

CNS Market Need

Aggression is a common feature in many psychiatric diseases. +50% in ADHD(***)

Global BPD market expected to grow to $2.6B in 2027

45 million people with AD worldwide; 20% shows aggresiveness

AD main disruptions: memory loss, aggression and apathy. AD global costs per annum of $605B

Oncology Market Need

Global AML market of $990m in 2019. Room for new Combos according to KoLs

SCLC is a serious unmet medical need, with a MOS of 8–12 months and 5% 2-year OSR

Global SCLC market +300,000 patients/y. FDA approved label extension of Pembro but only 19% of ORR (****)

Projections of Rova-T when in Phase III were +5B peak sales/y

(***) J Child Adolesc Psychopharmacol. 2016 Feb 1; 26(1): 19–25.
(****) Keynote study in 83 patients

ORYZON

ORYZON

A GLOBAL LEADER
IN CNS EPIGENETICS

VAFIDEMSTAT a Phase II Clinical Stage Compound with a broad developability in CNS diseases

ORYZON

Vafidemstat (ORY-2001): a “Neuron-fixer”

- Vafidemstat is a **small molecule** LSD1 inhibitor optimized for CNS
- **Excellent Pharmacology**. High **oral** bioavailability
- **Positive** results in **7 different animal models** and in i*n-vitro* models
  - Cognition
  - Neuroprotection
  - Neuroinflammation
  - Social Withdrawal / Apathy
  - Aggression / Agitation
  - Others
- Epigenetic **MoA** that modulates **neuroinflammation** and expression of key **plasticity neuronal genes**
- Biomarkers identified
- **Good Safety in humans in Phase I+II trials with +220 participants** so far
- **BBB penetrance** and (indirect) human brain target engagement established
- Pharmacologically active in humans

In Phase IIa in multiple clinical studies

Phase IIb studies under preparation

ORYZON

Vafidemstat, and LSD1 inhibition, improves cognition

In Alzheimer's SAMP8 model vafidemstat restores memory by the NORT model

In **Huntington disease** R6/1 model vafidemstat improves memory by the NORT model

In **Schizophrenia** SETD1a +/- model iadademstat (ORY-1001) improves working memory

In **Psychosis & Schizophrenia** NMDA receptor-hypofunction mice model T-448 (TAKEDA) LSD1 inhibitor improves memory

Vafidemstat Fully Restores Memory Measured by NORT in SAMP8 AD Model

MILD
MODERATE
SEVERE

Treatment from month 5 during 1 week (1), 1 month (2), 2 months (3), 4 months (4)
Treated from month 6 during 1 month (Delayed start-1) (5)
Treatment from month 5 during 1 month, tested at month 7 (1 month after treatment cessation) (6)
Treatment from month 8 during 4 months (Delayed start-2) (7)



Cognition and memory impairments are found in AD and dementias but also in Autism, Schizophrenia, Depression, Bipolar disorder and other psychiatric conditions

ORYZON

Vafidemstat Produces Significant Behavioural Changes

Vafidemstat Reduces Aggression in the Resident Intruder Test in the SAMP8 AD Mice model

Vafidemstat Enhances Sociability in the Three-Chamber Test in SAMP8 AD Mice



Vafidemstat Reduces Social Withdrawal in the Rat Isolation Model



MoA: an upstream epigenetic mechanism producing a dual activity, antinflammatory and prosynaptic

LSD1 localizes *in vivo* to enhancers and promoters of confirmed CNS disease risk genes

LSD1 binds to TFs that control IEG expression and stress in the PFC-amygdala axis, including SRF

- ✓ vafidemstat **up-regulates** genes associated with:
  - ✓ **Cognition,** notably memory and **executive functioning**
  - ✓ **Neuroplasticity**
- ✓ vafidemstat potentiates the response capacity of IEGs to stress
- ✓ vafidemstat **reduces** the expression of **inflammatory** genes including S100A9 and others



Inflammation signature genes

Cognitive function, neuroplasticity and memory

Vafidemstat potently **down-regulated** the expression of a subset of genes related to immune reaction and **inflammation as S100A9** involved in OPC defective remyelination

Genes **up-regulated** in SAMP8 mice by vafidemstat included

Baiap3: involved in retrograde trafficking

Prph: mutated in Amyotrophic Lateral Sclerosis (ALS),

Fabp7: upregulation in drosophila favors long term memory consolidation

Doc2a: activity-dependent modulator of excitatory synaptic transmission, relevant to memory formation

Kremen2 and Rspo1, regulators of the WNT pathway

LSD1 inhibition rescues the axon branching deficits in the Setd1a $^{+/-}$mice



In invitro axon branching rescue assays ORY-1001 was 1000-fold more potent than TCP

Mukai et al 2019 http://dx.doi.org/10.1101/529701
Recapitulation and reversal of schizophrenia-related phenotypes in *Setd1a*-deficient mice

ORYZON

Vafidemstat : Safety demonstrated in a Phase I study

Safe and well tolerated in a +100 healthy volunteers (young and elderly) Phase I (MAD+SAD) study

- No hematological impact at planned doses
- Efficiently crossed the BBB (70-90%)
- Oral PK - Half Life of 22h allowing once daily oral
- PK/PD data allowed definition of recommended Phase II doses

Safe and well tolerated so far in diverse Phase II studies

- Vafidemstat has been already administered to +220 volunteers and patients
- Phase IIs (MS, AD, ADHD, BPD and ASD patients) with no safety signals to date
- Longest exposure to date: 15 months

ORYZON

Vafidemstat: REIMAGINE - a Basket trial in aggression

Duration	**8 Weeks treatment + 4 weeks of follow up**		
Cohorts to be recruited			
Borderline Personality Disorder	6 patients	Done – Data reported in April 2019	upscaled later to an aggregated of 30 patients. **Recruitment completed**
Attention Deficit and Hyperactivity Disorder	6 patients	Done – Data reported in April 2019	
Autism Spectrum Disorder	6 patients	Done – Data reported in Sept 2019	

Endpoints

Safety

Efficacy:

Aggression / Agitation measured by CGI-S

Aggression / Agitation measured by CGI-I

Aggression / Agitation measured by NPI A/A 4 items

Psychiatric status measured by NPI Global assessment (12 items)

Change in specific disease scales

ORYZON

REIMAGINE the first proof of concept for vafidemstat in human patients

Patients of the three psychiatric indications: Borderline Personality Disorder (BPD) Attention Deficit and Hyperactivity Disorder (ADHD) and Autistic Spectrum Disorder (ASD) Treated With Vafidemstat Showed a Reduced Aggressivity

Secondary Endpoints: Efficacy

Data presented at CINP 2019

Significant improvements in aggression evaluated using the Neuropsychiatric Inventory 4-item agitation/aggression score **(NPI-A/A)**

NPI-A/A Agitation/Aggression (4 items)



Also significant improvements in aggression evaluated using the Clinical Global Impression of Severity **(CGI-S)** and Improvement **(CGI-I)** scales

REIMAGINE data presented at

EPA 2019 27th EUROPEAN CONGRESS OF PSYCHIATRY

7th World Congress on ADHD From Child to Adult Disorder 25 – 28 April 2019 Lisbon, Portugal

32ND ECNP CONGRESS 7-10 SEPTEMBER 2019 COPENHAGEN, DENMARK

CINP 2019 CINP International Meeting 3-5 October 2019 Athens, Greece

ORYZON

REIMAGINE the first proof of concept for vafidemstat in human patients

The significant improvements in the NPI global score and overall specific scales for BPD and ADHD suggest that vafidemstat has a **broader psychiatric effect beyond aggression**

Data presented at CINP 2019

Vafidemstat also produced significant improvements on the global NPI score (12 items) in BPD, ADHD and ASD patients

NPI Total score (12 items)

BPD



ADHD



ASD



All Patients



Remarkably, vafidemstat not only improved aggression but also produced significant improvement on the GLOBAL Borderline Personality Disease Checklist (BPDCL) scale

BPDCL Total score



Next steps: Vafidemstat, a meaningful therapeutic option for BPD

"I find myself able now to control my negative emotions and my frustration"

Patient with severe borderline personality disorder during treatment with vafidemstat. Testimony to her psychiatrist Dr. Marc Ferrer

The company recognizes a significant development potential for vafidemstat in psychiatric indications

- Vafidemstat may be a **disease modifying therapeutic option for BPD**: reduces aggression and produces an overall improvement of the core features of the disease, with **no sedation and no weight gain**
- BPD prevalence ranges between 0.5%-1.4% of the total population (≤ 9.1M in US+EU5)
- The treatment of BPD is now based on psychotherapeutic interventions. No drugs currently approved for this condition
- A **significant unmet medical need**
- Global **BPD Market,** 2018-2027 (US$), **$2.6B expected in 2027**



- **A new Phase IIb in BPD (*Portico)* under preparation**
- **Additional Phase IIb in adult aggressive ADHD (*Entrance)* and ASD *(Colonnade)* under evaluation**
- **And if +data in Reimagine-AD, a Phase IIb in AD aggressive patients (*Gateway)* will be performed**

ORYZON

Vafidemstat : a new therapeutic option for aggression in Alzheimer's disease

REIMAGINE - AD: A Phase IIa trial in Moderate and Severe AD

Duration	24 Weeks treatment + 4 weeks of follow up	
Open Label / Single arm (1.2mg/d)	12 patients	Recruitment Finished (Data report expected in April 2020)

- Safety
- Efficacy: Aggression / Agitation measured by NPI A/A 4 items, CMAI and CGI-A/A
- Memory status measured by MMSE
- Caregiver burden measured by changes in the Zarit Burden Interview (ZBI)

First proposition in AD: Vafidemstat as a symptomatic drug

- ✓ 45 million people affected worldwide
- ✓ 20% of the outpatients and 40% of the inmate patients display aggresiveness
- ✓ Vafidemstat is **safe and highly brain-penetrant** in humans
- ✓ Positive **effects** in different preclinical models on **memory, aggression, sociability and apathy**, all core features in AD patients
- ✓ Vafidemstat **reduces aggression in BPD, ADHD and ASD patients**

Vafidemstat may also provide clinical benefit in AD either as a single or multi-symptomatic drug or as a disease modifier

ORYZON

An ambitious Phase II trial, ETHERAL: Epigenetic THERapy in ALzheimer's Disease

Besides aggression, vafidemstat may provide also further benefits to AD patients

Phase IIa study to provide useful information to design future Phase II/III studies

- ✓ **150 Mild to Moderate AD** patients (6+6 months)
- ✓ Primary Objective: Safety & Tolerability
- ✓ Secondary Objectives:
  - ✓ Cognition/Agitation/Apathy/Depression/QoL
  - ✓ Volumetric MRI
- ✓ **Biomarker guided study** (with 8 CSF Biomarkers)

- ✓ 117 patients in EU. 17 sites
- ✓ Spain, France & UK

- ✓ A Twin study in US: around 25-28 patients
- ✓ IND approved mid March
- ✓ US Sites (3) opened
- ✓ FPI recruited in May



Vafidemstat appears to be safe in AD patients: ETHERAL first data report

One of the main goals in ETHERAL is to establish safety of vafidemstat in long-term administration, at therapeutically relevant doses in a frail and elder AD population

Vafidemstat treatment appears so far to be safe and well tolerated:

- Four SAEs were reported in three subjects, all suspected to be unlikely related to the treatment
- Platelet, neutrophils and other hematological parameters do not show clinically relevant variations due to vafidemstat treatment
- No abnormal and clinically significant liver enzymes levels or other laboratory findings have been reported to-date

Biomarker and other functional evolution in ETHERAL (blind analysis) is compatible with an informative study

Variations on the S100A9 CSF levels observed in the first 33 patients completing the first 24 weeks of therapy (blind analysis) might be compatible with the preclinical data that shows that vafidemstat decreases S100A9 levels in the CNS. S100A9 is a proinflammatory protein reported to be highly overexpressed in PFC in AD patients



individual patient CSF S100A9 Change from Baseline (CFB) is shown as fold induction after 24 weeks treatment

ORYZON

A GLOBAL LEADER
IN EPIGENETICS

Iadademstat

A Phase II stage clinical compound in Oncology

ORYZON

Iadademstat (ORY-1001): the most advanced selective LSD1 inhibitor in clinic

- ✓ LSD1 is involved in different cancers. **High levels of LSD1 often correlate with more aggressive forms of cancer and/or bad prognosis**
- ✓ Iadademstat is a small molecule that selectively inhibits LSD1. Preclinical positive *in vivo* results in different xenograft models. Best in Class. Full characterization published in top-rank journal.
- ✓ First LSD1i drug to enter into clinical trials. Encouraging results in a FiM Acute Leukemia Phase I/IIa trial



Cancer Cell
Article

CellPress

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

Tamara Maes,[1,6,*] Cristina Mascaró,[1] Iñigo Tirapu,[1] Angels Estiarte,[1] Filippo Ciceri,[1] Serena Lunardi,[1] Nathalie Guibourt,[1] Alvaro Perdones,[1] Michele M.P. Lufino,[1] Tim C.P. Somervaille,[2] Dan H. Wiseman,[2] Cihangir Duy,[3] Ari Melnick,[3,4] Christophe Willekens,[5] Alberto Ortega,[1] Marc Martinell,[1] Nuria Valls,[1] Guido Kurz,[1] Matthew Fyfe,[1] Julio Cesar Castro-Palomino,[1] and Carlos Buesa[1]

[1]Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornellà de Llobregat, Spain
[2]Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK
[3]Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, 10065 NY, USA
[4]Department of Pharmacology, Weill Cornell Medicine, New York, 10065 NY, USA
[5]Drug Development Department (DITEP) and Hematology Department, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
[6]Lead Contact
*Correspondence: tmaes@oryzon.com
https://doi.org/10.1016/j.ccell.2018.02.002

Phase I/IIa acute leukemia - previous data

- ✓ Safe and very well tolerated and therefore a meaningful candidate for combination with other agents
- ✓ PD Biomarkers identified in different subsets of leukemia
- ✓ Antileukemic activity observed in 29% of patients (12/41), including one CRi as Proof of Biological concept

ORYZON

Iadademstat a flexible CDP for a Large Market Opportunity

POTENTIAL ONCOLOGICAL INDICATIONS:

Solid Tumors

Small Cell Lung Cancer
Prostate cancer
Colorectal cancer
Bladder cancer
Some breast cancers
Merkel Cell Carcinoma

HemONC

AML
MDS
Myelofibrosis
Non Hodgkin
Lymphoma

Brain/rare Tumors

Medulloblastoma
Glioblastoma

MoA well characterized in SCLC, AML and Medulloblastoma

ORYZON

ALICE: An **A**ML trial with **L**SD1**i** in **C**ombination with azacitidine in the **E**lderly

A Phase IIa study to evaluate the safety, tolerability, dose finding and efficacy of iadademstat (ORY-1001) in combination with azacitidine in older patients with AML in first line therapy

- ✓ Single arm & Open label. Up to 36 patients to be enrolled
- ✓ **Primary endpoint**: Safety and tolerability of the combo with hypomethylating agent azacitidine
- ✓ **Secondary endpoints:** Responses; time to responses; duration of response; and overall survival

Preliminary Results
(5 evaluable patients out of 6)

EHA EUROPEAN HEMATOLOGY ASSOCIATION

- ✓ Combo **well tolerated**
- ✓ Fast responses (median time to response 1.5 months)
- ✓ **80% OR** (4/5 evaluable patients) : **75% CRi** and 25% PR
- ✓ 1 patient in CRi with decreasing need of transfusions
- ✓ Additional reports to be presented in future Medical Conferences



ORYZON

Iadademstat opportunity in Small Cell Lung Cancer (SCLC)

- ✓ LSD1 is a **target well characterized in SCLC** and validated in preclinical models. LSD1 inhibitors are effective in several in-vitro and in-vivo models of SCLC
- ✓ Iadademstat produces **complete and durable tumor regression** in different **chemoresistant PDX models**
- ✓ Characterized MoA
- ✓ Identified and patented Biomarkers that are differential in sensitive SCLC cell lines, tumors and plasma from patients
- ✓ Phase II trial ongoing in second line SCLC patients using these **biomarkers to stratify patients and identify super-responders**





ORYZON

Iadademstat: SCLC Current Clinical Development Plan

CLEPSIDRA: A **C**ombination trial of **L**SD1 and **E**top-**P**latinum in **S**mall Cell Lung Cancer in **biomarker-ID** **R**elapsed p**A**tients

A Phase IIa study to assess the safety, tolerability, dose finding and efficacy of iadademstat (ORY-1001) in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer who are positive to candidate predictive biomarkers

- ✓ Single arm
- ✓ Open label; 4 sites in Spain
- ✓ **Up to 36 patients to be enrolled**
- ✓ 4-6 cycles iadademstat+platinum/etoposide, thereafter iadademstat monotherapy (at investigators' criteria)
- ✓ **Primary end point**: Safety and tolerability of the combo with platinum-etoposide therapy
- ✓ **Secondary endpoints:** RECIST responses; time to responses; duration of response; and overall survival



Biomarker analysis from a CLEPSIDRA patient

Current status:

- ✓ **10 Patients enrolled. One patient at cycle 13**

ORYZON

Iadademstat: SCLC - Phase II CLEPSIDRA - preliminary efficacy signals

Preliminary Results

IASLC 2019 World Conference on Lung Cancer, September 7-10, 2019 | Barcelona, Spain

BARCELONA 2019 ESMO congress

- Main toxicity observed in the combination with carboplatin-etoposide is hematotoxicity
- **75% response rate** (6/8 evaluable patients): 4PRs and 2 long-term SD
- Current level of observed responses suggests that **patient selection by Biomarkers** may be effective to increase ratio of ORs
- **Iadademstat alone** is **safe** and **shows no hematological, general or neuronal toxicity** in ED-SCLC patients, suggesting potential for monotherapy and other combos
- Patient #1 showed initially 78.7% of tumor reduction after 6 cycles of triplet. Since then, and on iadademstat alone, patient is still in remission after 9 months (cycle 12) with 86.3% of tumor reduction by RECIST values and with all minor lesions still progressively being reduced or disappearing according to the 3 CT-Scans done since C6





CT-Scans for Patient #1 at screening, Cy6 and Cy12

More Results in future Medical Conferences

ORYZON

Anticipating a rich flow of catalysts / clinical data

Iadademstat Phase IIs in oncology

Vafidemstat Phase IIs in CNS

2019

CLEPSIDRA **ALICE**

REIMAGINE **ETHERAL** **SATEEN**

REIMAGINE-AD

April; Warsaw
BPD Aggression

April; Lisbon
ADHD Aggression

EPA 2019 27th EUROPEAN CONGRESS OF PSYCHIATRY — PSYCHIATRY IN TRANSITION: TOWARDS NEW MODELS, GOALS & CHALLENGES — Warsaw, Poland 6-9 April 2019

7th World Congress on ADHD — From Child to Adult Disorder — 25 – 28 April 2019 | Lisbon, Portugal

EHA EUROPEAN HEMATOLOGY ASSOCIATION

Amsterdam; June
AML data

IASLC 2019 World Conference on Lung Cancer — September 7-10, 2019 | Barcelona, Spain

Barcelona; Sept.
SCLC data

Sept.; Copenhagen
ASD Aggression

ECNP european college of neuropsychopharmacology

BARCELONA 2019 ESMO congress

Barcelona; Sept.
SCLC data

Oct.; Athens
Psychiatry Aggression

CINP

AMERICAN SOCIETY OF HEMATOLOGY

Orlando; Dec.
AML data

2020

April; Vienna
AD aggression
AD Global EU 6m data

AD/PD™2020 The 15th International Conference on Alzheimer's & Parkinson's Diseases

ASCO ANNUAL MEETING

Chicago; June
SCLC & AML data

July; Amsterdam
AD Global US 6m data

alzheimer's association AAIC 20

ORYZON

★ ★ *Potential Conferences where data may be presented*

ORYZON – a unique investment opportunity in an epigenetic platform

ORYZON

- A differential proposition in **EPIGENETICS** drugs in **CNS and ONCOLOGY** around one of the most interesting targets in the field: **LSD1**
- **2 molecules** in **Phase II** with promising clinical signals in human patients
- **Pioneers in CNS epigenetics**
  - Vafidemstat shows efficacy in psychiatric disorders (BPD, ADHD, ASD)
  - **Phase IIb in Borderline personality disorder under preparation**. Additional options in ADHD or ASD under evaluation
  - Vafidemstat may be also clinically relevant in neurodegenerative disorders (Phase IIs in MS and AD ongoing)
- **Most advanced** LSD1i (iadademstat) **in Oncology**
  - 2 Phase II trials ongoing in combo with respective SoC in AML and SCLC
  - **Positive preliminary efficacy results** reported from Phase II AML and SCLC trials
  - **SCLC trial is a biomarker-guided** study to stratify responsive patients
  - Options to get accelerated approval
- **Rich pipeline** of clinical **news** expected in the next 2-4 Qs
- Clinical Operations in US started and under expansion
- A **cash efficient** company with a seasoned international management team
- **€135M market cap**. One of the most liquid stocks in the microcap group in MadridSEXC
- Perseverant **presence in the US market in the last 4 years**. Two successful PIPEs executed in 2018-19 led by US Investment Banks and with participation of US investors
- A public company in Europe with **plans to** get dual listed in **NASDAQ**

ORYZON

EXPERIENCED MANAGEMENT TEAM

▪ CEO

CARLOS BUESA: **CEO & President. Spain/US**

PhD in Biochemistry and Molecular Biology.

Founder and CEO since inception.

Advanced programs on finance, business development, negotiation skills and human resources. He is also PADE at the IESE Business School.

Board Member of the VC Fund Inveready and VicePresident of the Spanish BioIndustry Association.

▪ CSO

TAMARA MAES: **CSO & VicePresident. Spain**

PhD in Biotechnology .

Founder and Chief Scientific Officer since inception. Responsible of the creation of the whole pipeline of the company and the biological target validation programs.

SAB member on several public institutions as CSIC (2009-2013) and private companies. Since 2016 Scientific Advisor of the ADDF .

▪ Medical Director

ROGER BULLOCK: **UK /PT/ Spain**

Chief Medical Officer

Graduated in Physiological Sciences at Keble College in Oxford University and got his MB.BS at London University.

Extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer's disease and other CNS conditions .

30-year research career, +than 100 peer-reviewed publications and book chapters.

He has worked as a consultant for companies active in the CNS space, including Lilly and Merck.

▪ VP Clinical Development

MICHAEL T. ROPACKI: US

Vice President of Clinical Development

PhD in Clinical Neuropsychology .

Dr. Ropacki has held roles of increasing responsibility for + 10y at Johnson & Johnson, his last as Director of Clinical Development, Neuroscience, Research and Development, for Janssen R&D serving as the Clinical Lead responsible for developing and leading the Cognitive Health in Aging Registry. Prior to that role he served as Global Medical Affairs Leader, Head of Late-Stage Development at Janssen AD Immunotherapy, LLC.

▪ Clin Ops Director

SONIA GUTIERREZ: Spain

Chief of Clinical Operations

BSc. Pharm. & MSc. & PDD in IESE Business School.

More than 20 years of experience in the clinical research and operations area at different International Pharma & Biotech companies.
CNS: +13y in Lundbeck involved in + 40 Clinical Trials in CNS.

Experience in oncology and other indications in Regeneron and other companies.

▪ IP Director

NEUS VIRGILI : Spain

Chief IP Officer

B.Sc. in Organic Chemistry from the University of Barcelona .

Qualified European Patent Attorney.

Over 20 years experience in pharmaceutical IP.

Since 2011 IP Officer at Oryzon.

▪ CFO

ENRIC RELLO: Spain

Chief Financial Officer

J.D.; PhD in Economics & Business Administration.

PLD - Program for Leadership Development, Harvard Business School.

BSc & MSc in Business Administration & Law.

HBS Finance Excell. Prog. Harvard Business School.

From 1997 till 2007 CFO of SANDOZ (NOVARTIS), Spanish Arm.

CFO at Oryzon since 2011.

▪ BDO

EMILI TORRELL: Spain

Chief BD Officer

B.Sc. in Sciences, Autonomous University of Barcelona.

MBA at ESADE and PDG at IESE Business School.

In the business development area from 1990 in the most relevant Spanish companies Prodesfarma, Almirall and Laboratorios Esteve.

From 2007 BD Director at Oryzon.

- An experienced and respected managerial team in the Biopharmaceutical industry
- Team members have a track record in product discovery & in advancing successfully through product development phases
- Demonstrated ability to close world class deals and to lead, and participate in international consortia

ORYZON

ORYZON
A GLOBAL LEADER
IN EPIGENETICS

CARLOS BUESA
CEO & President
cbuesa@oryzon.com

ROGER BULLOCK
Chief Medical Officer
rbullock@oryzon.com

TAMARA MAES
Chief Scientific Officer
tmaes@oryzon.com

MICHAEL ROPACKI
VP Clinical Development
mropacki@oryzon.com

ORYZON